Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Pre-market: 7.74-0.0500-0.64%08:31 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

Benzinga Earnings
·
Feb 26

Stock Track | ImmunityBio Soars 5.02% in Pre-market on Maintained Buy Rating from HC Wainwright & Co.

Stock Track
·
Feb 25

Stock Track | ImmunityBio Soars 5.28% on Maintained Buy Rating from HC Wainwright & Co.

Stock Track
·
Feb 25

ImmunityBio Director Barry J. Simon Disposes of Common Shares

Reuters
·
Feb 25

Stock Track | ImmunityBio Soars 5.80% Intraday on Maintained Buy Rating from HC Wainwright & Co.

Stock Track
·
Feb 24

Stock Track | ImmunityBio Soars 5.19% in Pre-market on Maintained Buy Rating

Stock Track
·
Feb 24

ImmunityBio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 24

ImmunityBio Founder Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation Cancer 2035 Summit

Reuters
·
Feb 24

ImmunityBio price target raised to $15 from $10 at H.C. Wainwright

TIPRANKS
·
Feb 24

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Benzinga Earnings
·
Feb 24

ImmunityBio rises 25.2%

TIPRANKS
·
Feb 23

BUZZ-ImmunityBio rises as cancer drug therapy sales surge, global approvals expand

Reuters
·
Feb 23

ImmunityBio Q4 EPS $(0.06) Beats $(0.09) Estimate, Sales $38.285M Beat $37.020M Estimate

Benzinga Earnings
·
Feb 23

Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $0.06 a Share, vs. FactSet Est of $0.09 Loss

MT Newswires Live
·
Feb 23

ImmunityBio FY 2025 net product revenue hits USD 113M on ~700% growth

Reuters
·
Feb 23

Immunitybio Reports 700% Year-Over-Year Revenue Growth, Expanded Anktiva® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries With Label Expansion Plans Globally

THOMSON REUTERS
·
Feb 23

Immunitybio Inc: Qtrly EPS $ -0.06

THOMSON REUTERS
·
Feb 23

Immunitybio Inc: Qtrly Total Revenue $38.3 Mln

THOMSON REUTERS
·
Feb 23

Mixed options sentiment in ImmunityBio with shares down 0.99%

TIPRANKS
·
Feb 21